T. Rowe Price Investment Management
WST icon

T. Rowe Price Investment Management’s West Pharmaceutical WST Stock Holding History

T. Rowe Price Investment Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$648M Sell
1,805,019
-535,384
-23% -$164M 0.42% 54
2026
Q1 		$587M Buy
2,340,403
+1,165,441
+99% +$290M 0.4% 67
2025
Q4 		$323M Buy
1,174,962
+473,547
+68% +$130M 0.2% 120
2025
Q3 		$184M Buy
701,415
+234,981
+50% +$57.1M 0.11% 187
2025
Q2 		$102M Buy
466,434
+4,361
+0.9% +$932K 0.06% 277
2025
Q1 		$103M Sell
462,073
-271,189
-37% -$74.7M 0.07% 272
2024
Q4 		$240M Sell
733,262
-106,048
-13% -$33.4M 0.15% 153
2024
Q3 		$252M Sell
839,310
-282,675
-25% -$86.6M 0.15% 157
2024
Q2 		$370M Buy
1,121,985
+35,960
+3% +$12.7M 0.23% 106
2024
Q1 		$430M Sell
1,086,025
-158,775
-13% -$58.7M 0.26% 101
2023
Q4 		$438M Sell
1,244,800
-381,064
-23% -$135M 0.29% 103
2023
Q3 		$610M Sell
1,625,864
-101,075
-6% -$39.1M 0.43% 65
2023
Q2 		$661M Buy
1,726,939
+7,011
+0.4% +$2.5M 0.45% 62
2023
Q1 		$596M Sell
1,719,928
-44
-0% -$12.9K 0.43% 61
2022
Q4 		$405M Buy
1,719,972
+12,228
+0.7% +$2.9M 0.31% 93
2022
Q3 		$420M Buy
+1,707,744
New +$520M 0.34% 83

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Investment Management's WST Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its West Pharmaceutical (WST) stake by 23% in Q2 2026, selling an estimated $164M and leaving 1,805,019 shares worth $648M. The position accounts for 0.42% of the portfolio, ranked #54.

T. Rowe Price Investment Management first reported a position in WST in Q3 2022 and has held it in 16 quarters since. The position peaked at $661M in Q2 2023. 827 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • T. Rowe Price Investment Management held 1,805,019 shares of West Pharmaceutical worth $648M as of Q2 2026.
  • T. Rowe Price Investment Management sold 535,384 West Pharmaceutical shares in Q2 2026, an estimated $164M.
  • West Pharmaceutical made up 0.42% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #54 holding.
  • T. Rowe Price Investment Management first reported a position in West Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • T. Rowe Price Investment Management's West Pharmaceutical position peaked at $661M in Q2 2023.
  • 827 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.